UNSPSC 51393309: Lodiperone

This classification denotes an anxiolytic with the molecular formula C21H20Cl2FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T8593BT7B4, chemically known as 5-(2-(4-(3,5-dichlorphenyl)-1-piperazinyl)ethyl)-4-(4-fluorphenyl)-4-oxazolin-2-on but generally known as lodiperone, which bears US NIH Compound Identifier 161849. European Medicines Agency schedules Lodiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08552MIG.

UNSPSC 51393309 Lodiperone, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The posted opportunity—Seminole County, Florida's IFB 60459723LAS for naloxone and safe drug deactivation systems—concerns emergency opioid-reversal medications and harm-reduction equipment, not lodiperone, which is an antipsychotic pharmaceutical. The mismatch suggests either a tagging error in the county's procurement system or that lodiperone has seen no recent state and local solicitation activity worth characterizing.

The single recent opportunity on record comes from Seminole County (Florida) under an IFB notice posted June 30, 2026, with a response deadline of July 26, 2023, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. That procurement calls for E-Verify compliance, workers' compensation and professional liability insurance, and a two-year initial term with an optional one-year renewal; the county notes potential FEMA funding and associated federal compliance requirements. No other recent state or local opportunities appear under this code. Without additional solicitations grounded in actual lodiperone procurement, the code shows insufficient activity to characterize geographic spread, issuing-body patterns, or market traction in state and local procurement.